The guidance raise and Pacira acquisition signal management's confidence in the growth trajectory, but the Nashik facility suspension and flat Q3 revenue temper the positive. Watch for Q4 2026 revenue impact from supply constraints and the closing of the Pacira deal, which will add non-opioid pain therapies to the portfolio.
Drug in focus
VTRS drug pipeline →MR-141 (phentolamine ophthalmic solution 0.75%)
● Neutral Named in this 8-K- Impact
- Phase
- Filed/sNDA under FDA review (Phase 3 completed)
- Time to market
- If approved at the October 17, 2026 PDUFA date, commercial launch could follow within weeks (Ryzumvi is already manufactured and marketed for its approved indication).
- Next catalyst
- None dated
What to watchWatch for the October 17, 2026 PDUFA decision on MR-141's presbyopia label expansion. Approval would add a differentiated non-pilocarpine presbyopia drop to Viatris's portfolio but faces crowded competition (Vuity, Qlosi, newly-approved Yuvezzi). For VTRS, this is a single positive catalyst in a broader turnaround story, not a stock-defining binary. The stock already rallied ~11% in 5 days on the sNDA acceptance news in Feb 2026.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $18.97entry
- T+1 · 11d ago +4.96%α +4.64% · $19.91
- T+5 · 5d ago +8.96%α +5.67% · $20.67
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Viatris reported Q3 2026 total revenues of $3.75B, essentially flat YoY, and adjusted EPS of $0.71, up 6% YoY and above the $0.64 consensus. The company raised its full-year 2026 guidance midpoints for all key metrics, announced a definitive agreement to acquire Pacira BioSciences for $1.65B, and disclosed that its Nashik, India facility received an Official Action Indicated classification and voluntarily suspended manufacturing. The combination of a guidance raise and a large acquisition offsets the flat revenue and manufacturing disruption.
Key Financial Metrics
Key Facts
- Q3 2026 total revenues $3.7495B, essentially flat YoY (Q3 2025: $3.7599B)
- Adjusted EPS $0.71, up 6% reported and 3% operational YoY, beating consensus of $0.64
- U.S. GAAP net loss of $325.3M vs loss of $128.2M in Q3 2025, driven by higher income tax provision
- Adjusted EBITDA $1.1957B, up 4% reported and 1% operational YoY
- Raised 2026 guidance midpoints: Total Revenues $14.7B-$14.9B (midpoint $14.8B), Adjusted EBITDA $4.45B-$4.55B, Adjusted EPS $2.56-$2.63, Free Cash Flow $2.225B-$2.375B
- Announced definitive agreement to acquire Pacira BioSciences for $36.50/share in cash, aggregate equity value of $1.65B, expected to close by end of November 2026
- FDA inspection classification of Nashik, India facility changed to Official Action Indicated; voluntary manufacturing suspension in October 2026, expected to resume in Q1 2027
- Supply constraints from Nashik impacted Q3 2026 revenue by approximately $100M, with another ~$100M expected in Q4 2026
- Returned approximately $717M of capital to shareholders YTD through September 30, 2026, including $300M in share repurchases
- FDA approved RYZUMVI for presbyopia in the U.S. and WAKIX in Japan
Financial Impact
Q3 revenue flat YoY at $3.75B; adjusted EPS $0.71 vs consensus $0.64; full-year guidance raised; $1.65B acquisition of Pacira; ~$200M total revenue impact from Nashik supply constraints in H2 2026
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Developed Markets | $2.2B | -2.0% |
| Greater China | $702.6M | +14.0% |
| JANZ | $287.1M | -6.0% |
| Emerging Markets | $529.1M | -7.0% |
Risk Factors
- Nashik facility suspension could extend beyond Q1 2027, worsening supply constraints
- Pacira acquisition integration risks and potential dilution or leverage increase
- Flat Q3 revenue and GAAP net loss widening YoY indicate underlying pressure from competition and supply issues
- Official Action Indicated classification may lead to further regulatory actions or remediation costs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001792044-26-000053 |
| Document: vtrs-20261105.htm | 0001792044-26-000053 |
| Document: 0001792044-26-000053-index-headers.html | 0001792044-26-000053 |
| Document: 0001792044-26-000053-index.html | 0001792044-26-000053 |
| Document: 0001792044-26-000053.txt | 0001792044-26-000053 |
| 8-K Data (Synthetic) | 0001792044-26-000053 |
Track record
22 reports on VTRS
3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +16.85% at T+60 after the Aug 6, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 17, 2026today 8-K Neutral 4/10 Entry $20.51 Now $20.49 −0.10% settles Feb 16
- Nov 17, 2026today Press Release Neutral 4/10 Entry $20.89 Now $20.49 −1.91% settles Feb 16
- Nov 16, 20261d ago SC 13G/A Neutral 2/10 Entry $20.84 Now $20.49 −1.68% settles Feb 12
- Nov 6, 202611d ago SC 13G/A Neutral 2/10 Entry $19.91 Now $20.49 +2.91% settles Feb 4
- Nov 5, 202612d ago 8-K Mixed 6/10 Viewing Entry $18.97 Now $20.49 +8.01% settles Feb 3
- Nov 4, 202613d ago Press Release Neutral 2/10 Entry $19.22 Now $20.49 +6.61% settles Feb 2
- Oct 30, 202618d ago Press Release Bullish 6/10 Entry $19.04 Now $20.49 +7.64% settles Jan 28
- Oct 29, 202619d ago Institutional Cluster Bullish 4/10 Entry $19.20 Now $20.49 +6.72% settles Jan 27
- Oct 16, 20264w ago Press Release Bullish 6/10 Entry $18.26 Now $20.49 +12.21% settles Jan 14
- Oct 8, 20265w ago 8-K Bullish 7/10 Entry $17.44 Now $20.49 +17.49% settles Jan 5
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers